Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17289123 | 0.87 | FAAH (0.65) | FAAHHTR1AHTR7OPRL1MCHR1 | |
| SCHEMBL1331198 | 0.87 | FAAH (0.65) | FAAHHTR1AHTR7OPRL1MCHR1 | |
| SCHEMBL27140396 | 0.82 | FAAH (0.57) | FAAHHTR1AHTR7MCHR1DRD4 | |
| SCHEMBL6584608 | 0.82 | FAAH (0.60) | FAAHHTR1AHTR7MCHR1DRD4 | |
| SCHEMBL28824423 | 0.81 | FAAH (0.56) | FAAHHTR1AHTR7OPRL1MCHR1 | |
| SCHEMBL6584428 | 0.80 | FAAH (0.59) | FAAHHTR1AHTR7OPRL1MCHR1 | |
| SCHEMBL1331766 | 0.79 | HRH3 (0.63) | FAAHHTR1AHTR7MCHR1DRD4 | |
| SCHEMBL2170401 | 0.79 | CYP3A4 (0.55) | FAAHHTR1AHTR7DRD4 | |
| SCHEMBL31061967 | 0.79 | CXCR4 (0.65) | FAAHHTR1AHTR7DRD4 | |
| SCHEMBL21066574 | 0.79 | CXCR4 (0.65) | FAAHHTR1AHTR7DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191483-B1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-9951010-B2 | Compounds as CRTH2 antagonist and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-3191483-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016037591-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | HRH2, PTGDR2, HRH1 | FAAH 144/4885HTR1A 467/4885HTR7 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.